Cross-reactivity with Diagnostic Products Corporation (DPC) amphetamine and methamphetamine radlolmmunoassay (RIA) reagents was determined for amphetamine, methamphetsmine, and a number of amphetamine analogs. Concentrations from 100 to 100,000 ng/mL were assayed. 3,4-Methylenedloxyamphetamlne (MDA) and 3,4-methylenedioxymethamphetmalne (MDMA) showed significant cross-reactivity for the amphetamine and methamphetamlne reagents respectively. 4-Hydroxymethamphetamine, 3,4-methylenedioxyethylamphetamlne (MDEA), and N,N-dimethyI-MDA also showed significant cross-reactivity with the methamphetamine reagents, but less than MDMA. None of the other analogs showed a positive result with the amphetamine or methamphetamine reagents at even the highest concentration, although several did show measurable crossreactivity. The L isomers of amphetamine and methamphetamine showed substantially less cross-reactivity than the n forms to which the respective antibody systems are targeted.
Introduction
Abuse of amphetamine, methamphetamine, and amphetamine analogs is neither a new nor unique phenomenon but is currently a significant problem. Although amphetamine abuse is not widespread in the U.S., methamphetamine abuse is and there is growing interest and concern over "ice", the solid form of methamphetamine. The use of amphetamine analogs poses not only societal concerns but also analytical challenges. Many amphetamine analogs from the illicit market of the 1960s have been reintroduced and new analogs have recently"surfaced. New analogs have been synthesized and marketed for increased potency, altered pharmacological effects, and difficulty of detection and prosecution. In some cases, synthesis of an analog yielded a compound not under the schedule of illegal drugs and which therefore could be prepared, marketed, and used without interference from law enforcement agencies. To address this problem, the Controlled Substance Analogue Act was enacted to prevent synthesis of new unscheduled drugs of abuse. Standard methods commonly used for screening biological samples for drugs of abuse may or may not detect an analog. Because of the ease of synthesis, numerous illicit analogs of amphetamine have appeared. The structure of amphetamine can be altered by substitution of the ethyl amine or on the benzene ring. These modifications may retain the stimulant properties of amphetamine or extend them. Recently several amphetamine analogs have been seen on the illicit market with increasing frequency. One of the most common is "esctasy" (MDMA), which remains popular even after its placement on the schedule of controlled substances in 1988. Other amphetamine analogs that have not been popular for some time have reappeared in clandestine laboratories. An example of this is the seizure of 4-bromo-2,5-dimethoxyamphetamine (DOB) by the DEA in 1989. Law enforcement efforts that address the starting materials for one illicit drug often prompt the synthesis from another starting material or the synthesis of another drug. To evaluate the ability of commercial screening methods to identify these compounds, a number of amphetamine analogs were tested with the double antibody for amphetamine assay and the Coat-a-Count methamphetamine assay from Diagnostic Products Corporation (DPC). Sample preparation. Solutions of test compounds were prepared in ethanol and stored at 4~ These drug solutions were mixed with negative control resulting in final concentrations ranging from 100 to 100,000 ng/mL.
Materials and Methods

Materials
Amphetamine test. Radiommunoassay analysis was per-
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formed with the double antibody for amphetamine from DPC essentially as described by the manufacturer (1,2) . For the amphetamine test, 25 #L of sample were placed into a 12-x 75-ram tube, to which was added 200 #L of '2'I amphetamine and 100 #L of amphetamine antiserum. The racks were shaken to thoroughly mix the components. After incubation at room temperature for an hour, 1.0 mL of the cold precipitating solution was added to each tube and the racks were again shaken. The racks were then centrifuged for 15 min at 3,000 g, the supernatant was decanted, and the precipitate counted on a Micromedic 10/600 gamma counter.
Methamphetamine test. The methamphetamine procedure with the Coat-a-Count methamphetamine reagents was similar to that of the amphetamine assay except it involved antibodycoated tubes rather than a double antibody system, thus eliminating addition of antibody solutions and centrifugation. 25 #L of sample was placed into a 12-x 75-mm methamphetamine antibody-coated polypropylene tube, to which was added 1.0 mL of '2'1 methamphetamine solution. The racks were shaken and then incubated at room temperature for one hour. The tubes were then thoroughly decanted to remove all liquid. The tubes were counted on a Micromedic 10/600 gamma counter. Positive and negative control solutions (provided by the manufacturer) were used to compare the cross-reactivity of the compounds tested to amphetamine or methamphetamine. Standard curves at 0, 500, 1,000, and 1,500 ng/mL analyte were analyzed with each batch of analogs tested. Each rack of 20 tubes also contained duplicate standards at the 0-and 1,000-ng/mL levels for evaluation of assay drift or decanting irregularities. Concentrations of the various amphetamine analogs were analyzed in quadruplicate. Average CPM determinations of replicates were used to determine percent cross-reactivity.
Data analysis. Quantitations were based on comparison of the mean CPM of four replicates for each compound at each concentration against a log-logit curve derived from five replicates of standards at 0, 500, 1,000, and 1,500 ng/mL of D-amphetamine for the amphetamine assay and o-methamphetamine for the methamphetamine assay. Any assay rack that showed values for the 0-or 1,000-ng/mL standards that were not within acceptable limits was repeated.
Results and Discussion
Behavior of the assay reagents for both amphetamine and methamphetamine was excellent. Precision data for both assays showed coefficients of variation (CV) less than 3% for all concentrations (Table I ). The coated-tube assay required a slightly different decanting technique, but the procedure was quickly mastered by personnel experienced with double antibody assays.
Substantial cross-reactivity was seen with MDA in the amphetamine assay. Results of the MDA analysis with the amphetamine reagents are shown in Table II . The value of 1,000 ng/mL was given specific significance in this study because it is defined as the positive cutoff level by the Department of Health and Human Services guidelines (3) and the Department of Defense and recommended by the manufacturer (1,2). Evaluation of results from the amphetamine reagents revealed that compounds with a substitution on the amine nitrogen showed substantially reduced cross-reactivity. The methylenedioxy group slightly enhanced binding with the antibody, but the presence of one or more methoxy groups on the ring substantially decreased binding to the antibody. Although all compounds tested in this study were consistent with this statement, 4-methoxyamphetamine was not tested and may be predicted to have higher cross-reactivity than methoxyamphetamines tested in this study. Structures of compounds that showed substantial crossreactivity are shown in Figure 1 . Results from compounds that did not demonstrate significant measurable cross-reactivity to the amphetamine reagents are found in Table III. MDMA demonstrated significant cross-reactivity to the methamphetamine reagents. The methylenedioxy group substantially enhanced the binding of the MDMA, giving a result equivalent to 1,000 ng/mL of D-methamphetamine at a concentration between 200 and 300 ng/mL. This high degree of cross-reactivity becomes even more significant when one considers that the MDMA in this study was the racemic mixture and racemic methamphetamine is only 67% cross-reactive when compared to D-methamphetamine at 1,000 ng/mL. MDEA and 4-hydroxymethamphetamine both gave positive results at concentrations of 2,000-3,000 ng/mL. The degree of cross-reactivity demonstrated with N,N-dimethyl-MDA would require approximately 25 #g/mL to produce a positive result (assuming a 1,000-ng/mL cutoff). Results of the MDMA, MDEA, 4-hydroxymethamphetamine, and N,N-dimethyl-MDA testing are shown in Table IV . For the methamphetamine reagents, an ethyl group on the amine nitrogen impeded but did not eliminate binding and the hydroxy group at the 4 position also did not eliminate binding. Addition of a second methyl group to the amine nitrogen substantially decreased binding as demonstrated by the N,N-dimethyl-MDA data. Methoxy groups at various positions on the ring also significantly decreased binding. Results of the other compounds tested with the methamphetamine reagents are shown in Table V .
The data show the L-isomers of amphetamine and methamphetamine to be significantly less reactive than the D-isomers. These results have important implications in the interpretation of data. In some countries, including the U.S., Vicks Inhalers contain 50 mg of L-methamphetamine (L-desoxyephedrine). With the advent of RIA reagents that are targeted specifically to D-methamphetamine, the potential for a positive result from use of an over-the-counter inhaler must be considered. Because of the low cross-reactivity of the L-isomer, a substantial amount of L-methamphetamine would be required to cause a positive result. Though this fact diminishes the probability of a positive result from a Vicks inhaler, a disadvantage of this low crossreactivity is that illicit methamphetamine synthesized from phenyl-2-propanone will be less cross-reactive (67~ for the D,L mixture) than that synthesized from ephedrine, thus decreasing the ability to detect the use of the drug. In addition, though L-methamphetamine has a legitimate use, it can still be abused. Because of the potential for a common over-the-counter medication to be identified as methamphetamine, it is imperative to identify the isomer present in the sample. This can easily be accomplished with the use of a chiral column or assymetrical derivatizing reagent in gas chromatography. The data reported in this study are limited to the radioimmunoassay results from the DPC reagents. Other studies of MDA, MDMA, and MDEA have been reported elsewhere for Syva EMIT (4, 5) and Abbott TDx (4) and for MDA and MDMA using the Abbott TDx system (6) . One of these reports also tested the Roche Abuscreen reagents with MDA, MDMA, and MDEA (4). Another study, using a group of analogs identical to those in the present study, reported the cross-reactivity with Roche Abuscreen amphetamine reagents (7) .
Immunoassay positive results for amphetamine and methamphetamine are not absolutely selective for the drug and can possibly be caused by a number of other phenethylamines, some of which are found in over-the-counter medications. Most overthe-counter medications have a reasonably low degree of cross- reactivity with the reagents used in this study (1, 2) , but the potential must not be ignored. Because the illicit analogs have a high abuse potential, it is important to be aware of their crossreactivity. In addition, when the use of an amphetamine analog is suspected, it is important to evalute negative RIA results with regard to these cross-reactivity data.
Conclusions
The reagents are fairly specific for the D-isomer of amphetamine and methamphetamine, which is generally considered a positive factor. Cross-reactivity of over-the-counter medications to the amphetamine reagents is quite low and very few positives would be expected to result from even fairly heavy use. The methamphetamine reagents have higher cross-reactivity and more samples will be positive due to the presence of over-thecounter medications. This can be a detrimental aspect of the reagents, unless the cross-reactivity to the illicit analogs is important, in which case the higher cross-reactivity is beneficial.
Of the amphetamine analogs tested, only MDA showed substantial cross-reactivity with the DPC amphetamine reagents. The cross-reactivity was slightly greater than that of am- Table III phetamine itself and any R1A positive urine that does not show the presence of amphetamine should be evaluated for MDA. The methamphetamine reagents showed substantial crossreactivity with MDMA, MDEA, 4-hydroxymethamphetamine, and N,N-dimethyl-MDA. MDMA was easily detected and the MDEA would likely identify users for a reasonable length of time. The cross-reactivity of the N,N-dimethyl-MDA was such that a positive result would only be seen for a relatively short period of time, because of the high concentration required to yield a positive result.
Other analogs tested did not show positive results with either the amphetamine or methamphetamine reagents (at a cutoff of 1,000 ng/mL) even at concentrations of 100/zg/mL. In cases of suspected use of amphetamine analogs other than those that showed significant cross-reactivity with one of the two reagent systems, it must be realized that one would not expect a positive RIA result. N-hydroxy-MDA, which has been sold on the illicit market under the guise of MDMA did not show significant cross-reactivity with either assay procedure.
Because of the lack of substantial cross-reactivity to many of the amphetamine analogs studied, use of this testing methodology is limited. Use of both reagent systems increases the capability of identifying amphetamine, methamphetamine, and their analogs in urine. Alternative methods should be investigated for detecting those analogs that did not demonstrate significant cross-reactivity. Because of the increased use of these compounds, it is important to have the ability to detect these drugs, particularly for cases in which their use is suspected.
